MEHD7945A

Known as: MEHD 7945A, MEHD-7945A 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2011-2017
012320112017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
PURPOSE Duligotuzumab is a dual-action antibody directed against EGFR and HER3. EXPERIMENTAL DESIGN mCRC patients with KRAS ex2… (More)
Is this relevant?
2017
2017
Aberrant signaling of the epidermal growth factor receptor (EGFR) plays a crucial role in the tumorigenesis of many cancer types… (More)
Is this relevant?
2016
2016
BACKGROUND This open-label, multicenter, phase Ib study assessed the safety and preliminary activity of duligotuzumab, a dual… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2016
2016
BACKGROUND Duligotuzumab, a novel dual-action humanized IgG1 antibody that blocks ligand binding to epidermal growth factor… (More)
Is this relevant?
2015
2015
PURPOSE The novel dual-action humanized IgG1 antibody MEHD7945A targeting HER3 and EGFR inhibits ligand-dependent HER dimer… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2015
2015
Human epidermal growth factor receptor family members (EGFR, HER2, HER3, and HER4) play important roles in tumorigenesis and… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2014
2014
Both abundant epidermal growth factor receptor (EGFR or ErbB1) and high activity of the phosphatidylinositol 3-kinase (PI3K)-Akt… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2013
Highly Cited
2013
EGF receptor (EGFR) inhibition is efficacious in cancer therapy, but initially sensitive tumors often develop resistance. In this… (More)
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Extensive crosstalk among ErbB/HER receptors suggests that blocking signaling from more than one family member may be essential… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2011
2011
MEHD7945A is a novel dual-action monoclonal antibody in which each of the two antigen-binding fragments is capable of binding to… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?